CME INFORMATION

Participants in this activity may receive up to 3 AMA PRA Category 1 Credits™.

Release date: October 2006                            Valid through: October 2008

Course Material

To receive real-time CME credit, read the course material and complete the multiple-choice assessment test and registration online. Participants have 2 opportunities to answer 8 out of 10 questions correctly. Then they may view the correct answers and complete the activity.

Target Audience

The target audience for the enduring CME activity is medical oncologists, radiation oncologists, oncology nurses, and other medical professionals involved in assessing, treating, and counseling patients with lung cancer.

Educational Objectives

Participants in this activity should be able to:

  • Assess issues and options for systemic chemotherapy in lung cancer patients.
  • Assess issues and options for the use of antiemetics and other factors in chemotherapy support.
  • Assess issues and options for treating bone complications in lung cancer.
  • Assess current approaches to recognizing and treating depression and anxiety in lung cancer patients
  • Discuss palliative and hospice care referral issues and options for patients with advanced disease.

Educational Need

Lung cancer treatment is multi-faceted, usually involving both multiple therapeutic approaches for the cancer itself as well as treatment for complications of the disease and of cancer therapies. Medical professionals who treat and counsel lung cancer patients need to be prepared to address a complex array of multidisciplinary information and issues as they assist patients and their families to balance treatment and end-of-life approaches.

Accreditation Statement

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity. InforMEDical designates this activity for a maximum of 3 AMA PRA Category 1 Credits™. Each participant should claim credit commensurate with the extent of his/her participation in the activity.

Faculty Disclosure Declarations

The following program faculty have reported financial relationships with commercial pharmaceutical, device or biotechnology companies as noted: Paul J. Hesketh: Merck: consultant, research support; MGI: consultant. Thomas J. Lynch, Jr.: AstraZeneca: consultant, Speakers’ Bureau; Genentech: consultant, Speakers’ Bureau; sanofi-aventis: consultant, Speakers’ Bureau. M. Dror Michaelson: Nothing to disclose. William F. Pirl: Forest: research support. Kevin A. Raskin: Stryker: fellowship support; Zimmer: fellowship support. Alan B. Sandler: Bristol-Myers Squibb: consultant; Eli Lilly: consultant; sanofi-aventis: consultant. Jennifer S.Temel: Amgen: research support; Eli Lilly: Speakers’ Bureau; Genentech: Speakers’ Bureau.

Off-label Usage Disclosure

This activity contains discussion of unlabeled and non-FDA approved uses of the following commercially available agents: bevacizumab, carboplatin, and cisplatin (lung cancer); and clonazepam, olanzapine, and quetiapine (anxiety).

Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Genentech, MGI PHARMA, Novartis Pharmaceuticals, sanofi-aventis U.S., any other manufacturer of pharmaceuticals or InforMEDical Communications, Inc. The drug selection and dosage information provided in this activity are believed to be accurate. However, participants are encouraged to consult the full prescribing information for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Educational Grant Support

This CME activity is supported by educational grants from Genentech, MGI PHARMA, Novartis Pharmaceuticals and sanofi-aventis U.S.